Eschatol recently disclosed the "Report on the Sale of Material Assets and Related Party Transactions (Draft)", in which the Company intends to sell its pharmaceutical business to Yuanli Investment, which is controlled by the state-owned enterprise Hunan Caixin Investment Holding Group Co., Ltd., Jiashan Investment, which is controlled by the State-owned Enterprise Jinshi Municipal Finance Bureau, and 7 counterparties, including Onlikang and Shengchuang Pharmaceutical, for RMB1.302 billion. Due to the debt relationship between the underlying assets and the company, after the debt is paid off, Yiduoli will receive 2.182 billion yuan in cash through the asset sale.
Vittorius said that the sale of the pharmaceutical sector is mainly to gather superior resources, strive to become a global benchmark enterprise for enzyme preparations and a leading enterprise in animal nutrition and health in China; optimize the asset-liability structure of listed companies to promote long-term sustainable development.
In the first half of the year, the revenue of feed additives reached 106 million yuan
Asia's largest manufacturer and service company of bioenzyme preparations
The company is the first professional production enterprise of biological enzyme preparations in China, the first listed enterprise in China's biological enzyme preparation industry, and the largest biological enzyme preparation manufacturing and service enterprise in Asia. In the first half of 2021, the operating income of the company's biological enzyme preparation plate reached 302 million yuan, an increase of 28.7% year-on-year. The company's biological enzyme preparations segment includes feed enzymes and food enzymes, washing enzymes and other industrial enzymes business, of which the field of feed enzymes, the company maintains an annual sales growth of 10%-15%. In the field of industrial enzyme preparations, the company relies on scientific research platforms such as the nationally recognized enterprise technology center to set up a number of industrial enzyme application research laboratories, and has obtained 201 national invention patents and 6 international patents, and its products cover washing, starch, alcohol, textile, papermaking and other fields.
In the animal nutrition and health business segment, the company's substitute antibody products have outstanding advantages. In the first half of 2021, the company's functional feed additive revenue reached 106 million yuan, a year-on-year increase of 60.98%, continuing the high growth momentum since the second half of 2020. Its main products of anti-resistance, BoLuohui Extract (veterinary drug API) and Boluohui (veterinary drug preparation), have obtained the national new veterinary drug certificate, and have excellent alternative antibiotic effects, and the product advantages are relatively unique.
The company said that under the continuous implementation of the national anti-resistance policy, the company will rely on the innovative technologies of biological enzyme preparations and plant extracts in the future, core products, channel customers and brand advantages to form an effective solution for feed substitute antibody products. At the same time, we will continue to expand functional feed additive products, cultivate new growth points, and strive to become a leading enterprise in functional feed additives in China.
The company disclosed the company's 2021 performance forecast in the same period, and the net profit attributable to the shareholders of the listed company in 2021 is expected to lose 90 million yuan to 110 million yuan.
The company said that after the completion of the transaction, the company will make use of the technology research and development advantages, product category advantages, brand advantages, channel advantages and customer resource advantages accumulated in the enzyme preparation industry in the past three decades, deeply cultivate enzyme preparations and agricultural and animal husbandry channels, and focus on the development of biological enzyme preparations, animal nutrition and health.
![Successfully slimmed down, 74-year-old Hillary is much slimmer and in a good mood to co-produce a documentary with Kardashian[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)